TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Editorial
Keywords: publishing, access to scientific informatio, scientific journals, internet, .
This article has 0 comments
Too valuable to put a price on
Access to information is essential for scientific progress, yet in many places it remains very limited. Given how easy it is to post an article on the web, where it is freely available to anyone who has access to the Internet, the current system based on subscription journals is coming increasingly into question (see Focus, p. 61). Governments, who foot the bill for most university libraries, and the charity sector, who are important sponsors of cancer research, are foremost among those
» Kathy Redmond
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.






